ID   CP51A_RAT               Reviewed;         503 AA.
AC   Q64654; Q64549;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   24-JUL-2024, entry version 177.
DE   RecName: Full=Lanosterol 14-alpha demethylase {ECO:0000303|PubMed:1872829, ECO:0000303|PubMed:8024575};
DE            Short=LDM {ECO:0000303|PubMed:7665087};
DE            EC=1.14.14.154 {ECO:0000269|PubMed:10544287, ECO:0000269|PubMed:11328599, ECO:0000269|PubMed:1872829, ECO:0000269|PubMed:3782148, ECO:0000269|PubMed:7665087};
DE   AltName: Full=CYPLI;
DE   AltName: Full=Cytochrome P450 51A1;
DE            Short=CYP51 {ECO:0000303|PubMed:10544287, ECO:0000303|PubMed:11328599};
DE   AltName: Full=Cytochrome P450-14DM {ECO:0000303|PubMed:1872829};
DE            Short=Cytochrome P45014DM;
DE   AltName: Full=Cytochrome P450LI;
DE   AltName: Full=Sterol 14-alpha demethylase P450 {ECO:0000303|PubMed:10544287, ECO:0000303|PubMed:11328599};
GN   Name=Cyp51a1 {ECO:0000303|PubMed:11328599, ECO:0000312|RGD:2481};
GN   Synonyms=Cyp51;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8024575; DOI=10.1006/bbrc.1994.1848;
RA   Aoyama Y., Funae Y., Noshiro M., Horiuchi T., Yoshida Y.;
RT   "Occurrence of a P450 showing high homology to yeast lanosterol 14-
RT   demethylase (P450(14DM)) in the rat liver.";
RL   Biochem. Biophys. Res. Commun. 201:1320-1326(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Wistar;
RX   PubMed=9498553; DOI=10.1093/oxfordjournals.jbchem.a021869;
RA   Noshiro M., Aoyama Y., Kawamoto T., Gotoh O., Horiuchi T., Yoshida Y.;
RT   "Structural and evolutionary studies on sterol 14-demethylase P450 (CYP51),
RT   the most conserved P450 monooxygenase: I. Structural analyses of the gene
RT   and multiple sizes of mRNA.";
RL   J. Biochem. 122:1114-1121(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 60-78; 223-231; 271-285;
RP   386-405; 437-446 AND 450-461, FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY
RP   REGULATION.
RC   TISSUE=Liver;
RX   PubMed=7665087; DOI=10.1016/0378-1119(95)00211-n;
RA   Sloane D.L., So O.Y., Leung R., Scarafia L.E., Saldou N., Jarnagin K.,
RA   Swinney D.C.;
RT   "Cloning and functional expression of the cDNA encoding rat lanosterol 14-
RT   alpha demethylase.";
RL   Gene 161:243-248(1995).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=3782148; DOI=10.1016/s0021-9258(19)75980-8;
RA   Trzaskos J.M., Fischer R.T., Favata M.F.;
RT   "Mechanistic studies of lanosterol C-32 demethylation. Conditions which
RT   promote oxysterol intermediate accumulation during the demethylation
RT   process.";
RL   J. Biol. Chem. 261:16937-16942(1986).
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=1872829; DOI=10.1016/0006-291x(91)91000-3;
RA   Aoyama Y., Yoshida Y.;
RT   "Different substrate specificities of lanosterol 14a-demethylase (P-
RT   45014DM) of Saccharomyces cerevisiae and rat liver for 24-methylene-24,25-
RT   dihydrolanosterol and 24,25-dihydrolanosterol.";
RL   Biochem. Biophys. Res. Commun. 178:1064-1071(1991).
RN   [7]
RP   PROTEIN SEQUENCE OF 52-81; 305-319; 324-334; 467-482 AND 488-499, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=8797093; DOI=10.1093/oxfordjournals.jbchem.a021331;
RA   Aoyama Y., Noshiro M., Gotoh O., Imaoka S., Funae Y., Kurosawa N.,
RA   Horiuchi T., Yoshida Y.;
RT   "Sterol 14-demethylase P450 (P45014DM*) is one of the most ancient and
RT   conserved P450 species.";
RL   J. Biochem. 119:926-933(1996).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY
RP   REGULATION.
RX   PubMed=10544287; DOI=10.1093/oxfordjournals.jbchem.a022536;
RA   Nitahara Y., Aoyama Y., Horiuchi T., Noshiro M., Yoshida Y.;
RT   "Purification and characterization of rat sterol 14-demethylase P450
RT   (CYP51) expressed in Escherichia coli.";
RL   J. Biochem. 126:927-933(1999).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF VAL-130; THR-136; PHE-139;
RP   ALA-144; TYR-227; ASP-231; HIS-314; THR-315 AND SER-316.
RX   PubMed=11328599; DOI=10.1093/oxfordjournals.jbchem.a002917;
RA   Nitahara Y., Kishimoto K., Yabusaki Y., Gotoh O., Yoshida Y., Horiuchi T.,
RA   Aoyama Y.;
RT   "The amino acid residues affecting the activity and azole susceptibility of
RT   rat CYP51 (sterol 14-demethylase P450).";
RL   J. Biochem. 129:761-768(2001).
CC   -!- FUNCTION: Sterol 14alpha-demethylase that plays a critical role in the
CC       cholesterol biosynthesis pathway, being cholesterol the major sterol
CC       component in mammalian membranes as well as a precursor for bile acid
CC       and steroid hormone synthesis (PubMed:10544287, PubMed:7665087).
CC       Cytochrome P450 monooxygenase that catalyzes the three-step oxidative
CC       removal of the 14alpha-methyl group (C-32) of sterols such as
CC       lanosterol (lanosta-8,24-dien-3beta-ol) and 24,25-dihydrolanosterol
CC       (DHL) in the form of formate, and converts the sterols to 4,4-dimethyl-
CC       5alpha-cholesta-8,14,24-trien-3beta-ol and 4,4-dimethyl-8,14-
CC       cholestadien-3beta-ol, respectively, which are intermediates of
CC       cholesterol biosynthesis (PubMed:10544287, PubMed:11328599,
CC       PubMed:1872829, PubMed:3782148, PubMed:7665087). Can also demethylate
CC       substrates not intrinsic to mammals, such as eburicol (24-methylene-
CC       24,25-dihydrolanosterol), but at a lower rate than DHL
CC       (PubMed:1872829). {ECO:0000269|PubMed:10544287,
CC       ECO:0000269|PubMed:11328599, ECO:0000269|PubMed:1872829,
CC       ECO:0000269|PubMed:3782148, ECO:0000269|PubMed:7665087}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 14alpha-methyl steroid + 3 O2 + 3 reduced [NADPH--
CC         hemoprotein reductase] = a Delta(14) steroid + formate + 4 H(+) + 4
CC         H2O + 3 oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:54028, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:138029, ChEBI:CHEBI:138031; EC=1.14.14.154;
CC         Evidence={ECO:0000269|PubMed:10544287, ECO:0000269|PubMed:11328599,
CC         ECO:0000269|PubMed:1872829, ECO:0000269|PubMed:3782148,
CC         ECO:0000269|PubMed:7665087};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54029;
CC         Evidence={ECO:0000269|PubMed:1872829, ECO:0000305|PubMed:10544287,
CC         ECO:0000305|PubMed:11328599, ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=lanosterol + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] =
CC         4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol + formate + 4
CC         H(+) + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:25286, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:16521, ChEBI:CHEBI:17813,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.154;
CC         Evidence={ECO:0000269|PubMed:10544287, ECO:0000269|PubMed:11328599,
CC         ECO:0000269|PubMed:1872829, ECO:0000305|PubMed:3782148,
CC         ECO:0000305|PubMed:7665087};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25287;
CC         Evidence={ECO:0000269|PubMed:1872829, ECO:0000305|PubMed:10544287,
CC         ECO:0000305|PubMed:11328599, ECO:0000305|PubMed:3782148,
CC         ECO:0000305|PubMed:7665087};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=24,25-dihydrolanosterol + 3 O2 + 3 reduced [NADPH--hemoprotein
CC         reductase] = 4,4-dimethyl-8,14-cholestadien-3beta-ol + formate + 4
CC         H(+) + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:45960, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:28113, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210, ChEBI:CHEBI:78904;
CC         Evidence={ECO:0000269|PubMed:10544287, ECO:0000269|PubMed:1872829,
CC         ECO:0000269|PubMed:3782148, ECO:0000269|PubMed:7665087};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45961;
CC         Evidence={ECO:0000269|PubMed:1872829, ECO:0000305|PubMed:10544287,
CC         ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 14alpha-methyl steroid + O2 + reduced [NADPH--hemoprotein
CC         reductase] = a 14alpha-hydroxymethyl steroid + H(+) + H2O + oxidized
CC         [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:68060, Rhea:RHEA-
CC         COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210, ChEBI:CHEBI:138029, ChEBI:CHEBI:176901;
CC         Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:68061;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 14alpha-hydroxymethyl steroid + O2 + reduced [NADPH--
CC         hemoprotein reductase] = a 14alpha-formyl steroid + H(+) + 2 H2O +
CC         oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:68064,
CC         Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210, ChEBI:CHEBI:176901, ChEBI:CHEBI:176902;
CC         Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:68065;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 14alpha-formyl steroid + O2 + reduced [NADPH--hemoprotein
CC         reductase] = a Delta(14) steroid + formate + 2 H(+) + H2O + oxidized
CC         [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:68068, Rhea:RHEA-
CC         COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15740,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:138031,
CC         ChEBI:CHEBI:176902; Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:68069;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=lanosterol + O2 + reduced [NADPH--hemoprotein reductase] = 32-
CC         hydroxylanosterol + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:75103, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16521, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:166806; Evidence={ECO:0000305|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75104;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=32-hydroxylanosterol + O2 + reduced [NADPH--hemoprotein
CC         reductase] = 32-oxolanosterol + H(+) + 2 H2O + oxidized [NADPH--
CC         hemoprotein reductase]; Xref=Rhea:RHEA:75107, Rhea:RHEA-COMP:11964,
CC         Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:166681, ChEBI:CHEBI:166806;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75108;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=32-oxolanosterol + O2 + reduced [NADPH--hemoprotein reductase]
CC         = 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol + formate + 2
CC         H(+) + H2O + oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:75111, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:17813, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210, ChEBI:CHEBI:166681;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75112;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=24,25-dihydrolanosterol + O2 + reduced [NADPH--hemoprotein
CC         reductase] = 32-hydroxy-24,25-dihydrolanosterol + H(+) + H2O +
CC         oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:75079,
CC         Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:28113,
CC         ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:87057;
CC         Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75080;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=32-hydroxy-24,25-dihydrolanosterol + O2 + reduced [NADPH--
CC         hemoprotein reductase] = 32-oxo-24,25-dihydrolanosterol + H(+) + 2
CC         H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:75087,
CC         Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210, ChEBI:CHEBI:87057, ChEBI:CHEBI:87060;
CC         Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75088;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=32-oxo-24,25-dihydrolanosterol + O2 + reduced [NADPH--
CC         hemoprotein reductase] = 4,4-dimethyl-8,14-cholestadien-3beta-ol +
CC         formate + 2 H(+) + H2O + oxidized [NADPH--hemoprotein reductase];
CC         Xref=Rhea:RHEA:75083, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:78904, ChEBI:CHEBI:87060;
CC         Evidence={ECO:0000269|PubMed:3782148};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75084;
CC         Evidence={ECO:0000305|PubMed:3782148};
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:Q16850};
CC   -!- ACTIVITY REGULATION: Inhibited by azalanstat (PubMed:7665087).
CC       Inhibited by azole antifungal agents ketoconazole, itraconazole and
CC       fluconazole (PubMed:10544287). {ECO:0000269|PubMed:10544287,
CC       ECO:0000269|PubMed:7665087}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=165 uM for lanosterol {ECO:0000269|PubMed:3782148};
CC         KM=10.5 uM for lanosterol {ECO:0000269|PubMed:10544287};
CC         KM=312 uM for 24,25-dihydrolanosterol {ECO:0000269|PubMed:3782148};
CC         KM=20.0 uM for 24,25-dihydrolanosterol {ECO:0000269|PubMed:10544287};
CC         Vmax=3390 pmol/min/mg enzyme toward lanosterol
CC         {ECO:0000269|PubMed:3782148};
CC         Vmax=13.9 nmol/min/nmol enzyme toward lanosterol
CC         {ECO:0000269|PubMed:10544287};
CC         Vmax=645 pmol/min/mg enzyme toward 24,25-dihydrolanosterol
CC         {ECO:0000269|PubMed:3782148};
CC         Vmax=20.0 nmol/min/nmol enzyme toward 24,25-dihydrolanosterol
CC         {ECO:0000269|PubMed:10544287};
CC   -!- PATHWAY: Steroid biosynthesis; zymosterol biosynthesis; zymosterol from
CC       lanosterol: step 1/6. {ECO:0000305|PubMed:7665087}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000305|PubMed:8797093}; Single-pass membrane protein
CC       {ECO:0000255}. Microsome membrane {ECO:0000269|PubMed:8797093}; Single-
CC       pass membrane protein {ECO:0000255}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA87074.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D55681; BAA09529.1; -; mRNA.
DR   EMBL; AB004096; BAA20354.1; -; Genomic_DNA.
DR   EMBL; BC087033; AAH87033.1; -; mRNA.
DR   EMBL; U17697; AAA87074.1; ALT_FRAME; mRNA.
DR   PIR; JC4240; JC4240.
DR   PIR; JC4758; JC4758.
DR   RefSeq; NP_037073.1; NM_012941.2.
DR   AlphaFoldDB; Q64654; -.
DR   SMR; Q64654; -.
DR   BioGRID; 247462; 1.
DR   STRING; 10116.ENSRNOP00000009985; -.
DR   BindingDB; Q64654; -.
DR   ChEMBL; CHEMBL4981; -.
DR   DrugCentral; Q64654; -.
DR   SwissLipids; SLP:000001302; -.
DR   PhosphoSitePlus; Q64654; -.
DR   jPOST; Q64654; -.
DR   PaxDb; 10116-ENSRNOP00000009985; -.
DR   Ensembl; ENSRNOT00000009985.6; ENSRNOP00000009985.3; ENSRNOG00000007234.6.
DR   Ensembl; ENSRNOT00055002837; ENSRNOP00055002121; ENSRNOG00055001760.
DR   Ensembl; ENSRNOT00060028958; ENSRNOP00060023314; ENSRNOG00060016934.
DR   Ensembl; ENSRNOT00065030601; ENSRNOP00065024339; ENSRNOG00065018261.
DR   GeneID; 25427; -.
DR   KEGG; rno:25427; -.
DR   UCSC; RGD:2481; rat.
DR   AGR; RGD:2481; -.
DR   CTD; 13121; -.
DR   RGD; 2481; Cyp51.
DR   eggNOG; KOG0684; Eukaryota.
DR   GeneTree; ENSGT00930000151026; -.
DR   HOGENOM; CLU_001570_15_0_1; -.
DR   InParanoid; Q64654; -.
DR   OMA; AWTLIEL; -.
DR   OrthoDB; 5474434at2759; -.
DR   PhylomeDB; Q64654; -.
DR   TreeFam; TF105091; -.
DR   BRENDA; 1.14.14.154; 5301.
DR   Reactome; R-RNO-191273; Cholesterol biosynthesis.
DR   Reactome; R-RNO-211976; Endogenous sterols.
DR   UniPathway; UPA00770; UER00754.
DR   PRO; PR:Q64654; -.
DR   Proteomes; UP000002494; Chromosome 4.
DR   Bgee; ENSRNOG00000007234; Expressed in duodenum and 21 other cell types or tissues.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020037; F:heme binding; ISO:RGD.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016491; F:oxidoreductase activity; IBA:GO_Central.
DR   GO; GO:0008398; F:sterol 14-demethylase activity; IDA:RGD.
DR   GO; GO:0033488; P:cholesterol biosynthetic process via 24,25-dihydrolanosterol; IDA:RGD.
DR   GO; GO:1900222; P:negative regulation of amyloid-beta clearance; ISO:RGD.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; ISO:RGD.
DR   GO; GO:0050709; P:negative regulation of protein secretion; ISO:RGD.
DR   GO; GO:0060282; P:positive regulation of oocyte development; IMP:RGD.
DR   GO; GO:0045540; P:regulation of cholesterol biosynthetic process; TAS:RGD.
DR   GO; GO:0044752; P:response to human chorionic gonadotropin; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0010288; P:response to lead ion; IEP:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IEP:RGD.
DR   GO; GO:0006694; P:steroid biosynthetic process; ISO:RGD.
DR   GO; GO:0016125; P:sterol metabolic process; IBA:GO_Central.
DR   CDD; cd11042; CYP51-like; 1.
DR   Gene3D; 1.10.630.10; Cytochrome P450; 1.
DR   InterPro; IPR050529; CYP450_sterol_14alpha_dmase.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   PANTHER; PTHR24304:SF2; 24-HYDROXYCHOLESTEROL 7-ALPHA-HYDROXYLASE; 1.
DR   PANTHER; PTHR24304; CYTOCHROME P450 FAMILY 7; 1.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00465; EP450IV.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; Cytochrome P450; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Cholesterol biosynthesis; Cholesterol metabolism;
KW   Direct protein sequencing; Endoplasmic reticulum; Heme; Iron;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Metal-binding; Microsome;
KW   Monooxygenase; Oxidoreductase; Reference proteome; Steroid biosynthesis;
KW   Steroid metabolism; Sterol biosynthesis; Sterol metabolism; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..503
FT                   /note="Lanosterol 14-alpha demethylase"
FT                   /id="PRO_0000052001"
FT   TRANSMEM        24..44
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   BINDING         449
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000250|UniProtKB:Q16850"
FT   MUTAGEN         130
FT                   /note="V->A: Decreases lanosterol 14-alpha demethylase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         136
FT                   /note="T->A,V: Decreases lanosterol 14-alpha demethylase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         139
FT                   /note="F->A: Impairs lanosterol 14-alpha demethylase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         144
FT                   /note="A->I,V: Decreases lanosterol 14-alpha demethylase
FT                   activity. Increases the susceptibility to ketoconazole."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         227
FT                   /note="Y->A: Significantly decreases lanosterol 14-alpha
FT                   demethylase activity. Increases the susceptibility to
FT                   ketoconazole."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         231
FT                   /note="D->A,E: Significantly decreases lanosterol 14-alpha
FT                   demethylase activity."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         314
FT                   /note="H->F,A,K,D: Significantly decreases lanosterol 14-
FT                   alpha demethylase activity. Increases the susceptibility to
FT                   ketoconazole."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         315
FT                   /note="T->A,V,K,N: Impairs lanosterol 14-alpha demethylase
FT                   activity. Increases the susceptibility to ketoconazole."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   MUTAGEN         316
FT                   /note="S->T,V,L: Significantly decreases lanosterol 14-
FT                   alpha demethylase activity."
FT                   /evidence="ECO:0000269|PubMed:11328599"
FT   CONFLICT        181
FT                   /note="E -> K (in Ref. 4; AAA87074)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   503 AA;  56707 MW;  33D8F345FFE9CF21 CRC64;
     MVLLGLLQSG GSVLGQAMEQ VTGGNLLSTL LIACAFTLSL VYLFRLAVGH MVQLPAGAKS
     PPYIYSPIPF LGHAIAFGKS PIEFLENAYE KYGPVFSFTM VGKTFTYLLG SDAAALLFNS
     KNEDLNAEEV YGRLTTPVFG KGVAYDVPNA VFLEQKKILK SGLNIAHFKQ YVSIIEKEAK
     EYFKSWGESG ERNVFEALSE LIILTASHCL HGKEIRSQLN EKVAQLYADL DGGFSHAAWL
     LPGWLPLPSF RRRDRAHREI KNIFYKAIQK RRLSKEPAED ILQTLLDSTY KDGRPLTDDE
     IAGMLIGLLL AGQHTSSTTS AWMGFFLARD KPLQDKCYLE QKTVCGEDLP PLTYEQLKDL
     NLLDRCIKET LRLRPPIMTM MRMAKTPQTV AGYTIPPGHQ VCVSPTVNQR LKDSWVERLD
     FNPDRYLQDN PASGEKFAYV PFGAGRHRCI GENFAYVQIK TIWSTMLRLY EFDLINGYFP
     SVNYTTMIHT PENPVIRYKR RSK
//
